adoptive immunotherapy utilizing human recombinant interleukin 2 ( ril-2 ) in conjunction with lymphokine-activated killer cells has shown some efficacy in the treatment of various types of cancers , particularly renal carcinoma and melanoma .
C0006826
cancers
C0025202
melanoma